MDXG - MiMedx gets FDA warning letter over Axiofill production
2023-12-29 18:01:59 ET
More on MiMedx Group
- MiMedx Group, Inc. (MDXG) Q3 2023 Earnings Call Transcript
- Unraveling MiMedx's Surgical Precision In Growth
- MiMedx adds 30M shares on conversion of preferred stock
- MiMedx Group Non-GAAP EPS of $0.05 in-line, revenue of $81.71M beats by $3.77M
- Seeking Alpha’s Quant Rating on MiMedx Group
For further details see:
MiMedx gets FDA warning letter over Axiofill production